Sanofi ADS (SNY)

FairStock Score: 62/100 — STEADY

Key Financials

Strengths

• Generates $16.6 billion in annual free cash flow (14.6% yield on market cap)
• Strong Piotroski F-Score of 7/9 indicating robust financial health across profitability, leverage, and efficiency metrics
• Conservative balance sheet with debt-to-equity of just 0.28, providing financial flexibility
• Revenue growth of 59.9% demonstrates strong top-line momentum
• Attractive 5.2% dividend yield providing steady income returns

Concerns

• Altman Z-Score of 1.4 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Sanofi ADS is a large-cap healthcare company valued at $114.2 billion. The business generates $46.7 billion in annual revenue with a 3.5% net margin and $16.6 billion in free cash flow. From a quality standpoint, Sanofi shows solid Piotroski F-Score of 7/9 and distressed Altman Z-Score of 1.4 warrants caution. On valuation, the stock is reasonably priced at 20.0x earnings, with a modest 16% margin of safety vs Graham Number. Growth dynamics show revenue growing at 59.9% and profit growth of -260.5%. The 5.2% dividend yield adds an income component for patient holders. Our composite FairStock Score of 64/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Sanofi's 60% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $16.6 billion in annual free cash flow (14.6% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer